Abstract:The core Hippo pathway module consists of a tumor‐suppressive kinase cascade that inhibits the transcriptional coactivators Yes‐associated protein (YAP) and WW domain‐containing transcription regulator protein 1 (WWTR1; also known as TAZ). When the Hippo pathway is downregulated, as often occurs in breast cancer, YAP/TAZ activity is induced. To elaborate the roles of TAZ in triple‐negative breast cancer (TNBC), we depleted Taz in murine TNBC 4T1 cells, using either CRISPR/Cas9 or small hairpin RNA (shRNA). TAZ‐depleted cells and their controls, harboring wild‐type levels of TAZ, were orthotopically injected into the mammary fat pads of syngeneic BALB/c female mice, and mice were monitored for tumor growth. TAZ depletion resulted in smaller tumors compared to the tumors generated by control cells, in line with the notion that TAZ functions as an oncogene in breast cancer. Tumors, as well as their corresponding in vitro cultured cells, were then subjected to gene expression profiling by RNA sequencing (RNA‐seq). Interestingly, pathway analysis of the RNA‐seq data indicated a TAZ‐dependent enrichment of 'Inflammatory Response', a pathway correlated with TAZ expression levels also in human breast cancer tumors. Specifically, the RNA‐seq analysis predicted a significant depletion of regulatory T cells (Tregs) in TAZ‐deficient tumors, which was experimentally validated by the staining of tumor sections and by quantitative cytometry by time of flight (CyTOF). Strikingly, the differences in tumor size were completely abolished in immune‐deficient mice, demonstrating that the immune‐modulatory capacity of TAZ is critical for its oncogenic activity in this setting. Cytokine array analysis of conditioned medium from cultured cells revealed that TAZ increased the abundance of a small group of cytokines, including plasminogen activator inhibitor 1 (Serpin E1; also known as PAI‐1), CCN family member 4 (CCN4; also known as WISP‐1) and interleukin‐23 (IL‐23), suggesting a potential mechanistic explanation for its in vivo immunomodulatory effect. Together, our results imply that TAZ functions in a non‐cell‐autonomous manner to modify the tumor immune microenvironment and dampen the anti‐tumor immune response, thereby facilitating tumor growth.

Transcriptomics analysis revealed that TAZ regulates the proliferation of KIRC cells through mitophagy

RCC1 functions as a tumor facilitator in clear cell renal cell carcinoma by dysregulating cell cycle, apoptosis, and EZH2 stability

Taz Promotes Cell Proliferation and Epithelial-Mesenchymal Transition and is Inhibited by the Hippo Pathway

Tead Transcription Factors Mediate the Function of Taz in Cell Growth and Epithelial-Mesenchymal Transition

The Hippo Pathway Effector Transcriptional Co-activator With PDZ-Binding Motif Correlates With Clinical Prognosis and Immune Infiltration in Colorectal Cancer

Taz Regulates Cell Proliferation and Sensitivity to Vitamin D3 in Intrahepatic Cholangiocarcinoma

MZT2A serves as a prognostic biomarker and promotes the progression of kidney renal clear cell carcinoma

Downregulation of AZGP1 by Ikaros and Histone Deacetylase Promotes Tumor Progression Through the PTEN/Akt and CD44s Pathways in Hepatocellular Carcinoma.

TAZ facilitates breast tumor growth by promoting an immune‐suppressive tumor microenvironment

TROAP Promotes the Proliferation, Migration, and Metastasis of Kidney Renal Clear Cell Carcinoma with the Help of STAT3

High Expression of Taz Indicates A Poor Prognosis in Retinoblastoma

Bioinformatics Analysis of the Prognostic and Biological Significance of ZDHHC-Protein Acyltransferases in Kidney Renal Clear Cell Carcinoma

TAZ Expression As a Prognostic Indicator in Colorectal Cancer.

Hippo Transducer Taz Promotes Epithelial Mesenchymal Transition and Supports Pancreatic Cancer Progression

The Hippo transducer TAZ promotes cell proliferation and tumor formation of glioblastoma cells through EGFR pathway

A positive feedback loop between TAZ and miR-942-3p modulates proliferation, angiogenesis, epithelial-mesenchymal transition process, glycometabolism and ROS homeostasis in human bladder cancer

Oncogenic Chromatin Modifier KAT2A Activates MCT1 to Drive the Glycolytic Process and Tumor Progression in Renal Cell Carcinoma

Functional and Clinical Evidence That TAZ is a Candidate Oncogene in Hepatocellular Carcinoma

ZNF582 overexpression restrains the progression of clear cell renal cell carcinoma by enhancing the binding of TJP2 and ERK2 and inhibiting ERK2 phosphorylation

Regulation and Function of the TAZ Transcription Co-Activator.

TGFBI Promotes Proliferation and Epithelial–mesenchymal Transition in Renal Cell Carcinoma Through PI3K/AKT/mTOR/HIF-1α Pathway